1, "market value+net profit" standard: the market value is not less than 1 billion, and it has been profitable for two consecutive years, and the accumulated net profit after deducting non-profit in the last two years is not less than 50 million; Or the market value is not less than 654.38+0 billion, and the profit in the latest year is not less than 654.38+0 billion.
2. The standard of "market value+income +R&D investment": the market value is not less than 65.438+0.5 billion, the revenue in the latest year is not less than 200 million, and the proportion of total R&D investment in the last three years is not less than 654.38+00% of the total accounts receivable in the last three years.
3. The standard of "market value+income+cash flow": the market value is not less than 2 billion, the revenue in the latest year is not less than 300 million, and the accumulated net cash flow from business activities in the last three years is not less than 654.38 billion.
4. "Market value+income" standard: the market value is not less than 3 billion, and the revenue in the latest year is not less than 300 million.
5. "Independent enrollment" standard: the market value is not less than 4 billion, and the main products or market space is large; Or approved by the relevant state departments, and achieved phased results; Or get a certain amount of investment from well-known investment institutions; Or the pharmaceutical enterprise has obtained the approval of at least one second-phase clinical trial of the first-class new drug; Or other enterprises that meet the positioning of science and technology innovation board should have obvious technological advantages and reach certain standards.